Multiple Myeloma Scorecard: Efficacy, Cost, and Safety
New study compares published data from various treatment regimens for multiple myeloma, scoring them on efficacy, cost, and adverse effects.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing. -
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection. -
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate. -
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Gene-Expression Profiling Assay Predicts Survival in Newly Diagnosed Multiple Myeloma
Real-World Trends in the Assessment of Minimum Residual Disease in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Increased Risk of Venous Thromboembolism in Patients With Myelofibrosis
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
